ARCT News and Press, Arcturus Therapeutics Ltd.

Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasda...

2024-06-19 20:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-09 20:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-08 02:42:56 ET Summary Arcturus is a top pick in the biotech sector with a strong stock market performance. The company generates revenue from research and development partnerships, which helps conserve cash. The launch of the Kostaive vaccine and other programs are ex...

2024-06-07 15:15:02 ET William Blair analyst issues OUTPERFORM recommendation for ARCT on June 7, 2024 02:23PM ET. The previous analyst recommendation was Outperform. ARCT was trading at $30.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-06-07 14:23:26 ET More on NASDAQ Composite Index, S&P 500 Index, etc. The Fed Preview: Hawkish Turn Straight Into The Recession S&P 500 Earnings: Forward Estimates Continue To Be Revised Higher May Jobs Report: Surging Payrolls Likely Temper Rate Expecta...

2024-06-07 12:46:11 ET More on Arcturus Therapeutics Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis Arcturus gains after early-stage data for cystic fibros...

ARCT-032 is safe and well tolerated with no serious adverse events (SAEs) in 36 study participants, including 4 adults with cystic fibrosis (CF) Phase 1b interim data includes a CF participant with Class 1 mutations and three participants with F508del mutations being treated with Trik...

2024-05-30 11:50:35 ET Summary Vertex Pharmaceuticals has a strong focus on cystic fibrosis, which is driving revenue growth and pipeline development. The company has outperformed Johnson & Johnson and the S&P 500 in terms of total returns. Near-term catalysts include ...

2024-05-28 09:04:37 ET More on Arcturus Therapeutics Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earn...